KEYTRUDA 100 MG/ 4 ML IV FLC

KEYTRUDA is a prescription medication used in immunotherapy to treat various types of cancer. It contains the active ingredient pembrolizumab, which is a monoclonal antibody designed to inhibit the programmed cell death protein 1 (PD-1) receptor. By blocking PD-1, KEYTRUDA helps to enhance the body’s immune system to recognize and attack cancer cells. How It Works KEYTRUDA is an immune checkpoint inhibitor. It works by targeting and blocking the PD-1 receptor on the surface of immune cells. Normally, the PD-1 receptor helps prevent immune cells from attacking normal cells. Cancer cells often exploit this pathway to evade immune detection and destruction. By inhibiting PD-1, KEYTRUDA helps the immune system to recognize and destroy cancer cells more effectively. Indications KEYTRUDA is approved for the treatment of several types of cancer, including: Non-Small Cell Lung Cancer (NSCLC) Melanoma Head and Neck Squamous Cell Carcinoma (HNSCC) Hodgkin Lymphoma Urothelial Carcinoma Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors Esophageal Cancer Primary Mediastinal B-Cell Lymphoma (PMBCL) Cervical Cancer Cutaneous Squamous Cell Carcinoma (CSCC) Side Effects Common side effects of KEYTRUDA include: Fatigue Nausea Pruritus (itching) Rash Decreased appetite Diarrhea Cough Fever Serious side effects may include: Immune-mediated pneumonitis (lung inflammation) Immune-mediated colitis (inflammation of the colon) Immune-mediated hepatitis (liver inflammation) Immune-mediated endocrinopathies (endocrine gland inflammation) Severe infections Infusion reactions Contraindications KEYTRUDA is contraindicated in: Patients with a known hypersensitivity to pembrolizumab or any of the excipients of the product. Patients with severe, active autoimmune diseases that may be exacerbated by immune system activation. Patients who are pregnant or breastfeeding, due to potential risks to the fetus or infant. Price Table (in Different Countries) Below is an HTML table showing approximate prices for KEYTRUDA 100 MG/4 ML IV FLC in various countries. Prices may vary and are subject to change.

KEYTRUDA 100 MG/4 ML IV FLC Price Comparison

Country	Price (USD)	Reference
United States	$10,000	GoodRx
United Kingdom	£7,500	NICE
Canada	CAD $12,000	CADTH
Australia	AUD $14,000	PBS
Germany	€9,000	G-BA

Top 5 Global Brands Merck & Co., Inc. (Manufacturer of KEYTRUDA) Bristol-Myers Squibb (Known for Opdivo, another PD-1 inhibitor) Roche (Manufacturer of Tecentriq, an anti-PD-L1 therapy) AstraZeneca (Known for Imfinzi, another immune checkpoint inhibitor) Novartis (Manufacturer of Kymriah, though it’s a CAR T-cell therapy, it competes in the immunotherapy space)